N
ANRO icon

Nuveen’s Alto Neuroscience ANRO Stock Holding History

Nuveen’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-139,953
Closed -$302K – 3430
2025
Q1 		$302K Hold
139,953
– – ﹤0.01% 3042
2024
Q4 		$592K Sell
139,953
-61,310
-30% -$383K ﹤0.01% 2927
2024
Q3 		$2.3M Buy
201,263
+163,564
+434% +$2M ﹤0.01% 2341
2024
Q2 		$403K Buy
+37,699
New +$491K ﹤0.01% 3061

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Nuveen's ANRO Position: Q2 2025 in Review

Nuveen sold out of Alto Neuroscience (ANRO) in Q2 2025, closing a stake of 139,953 shares — an estimated $302K sold.

Nuveen first reported a position in ANRO in Q2 2024 and held it in 4 quarters. The position peaked at $2.3M in Q3 2024. 80 funds tracked by Wall St. Rank hold ANRO as of Q2 2025.

  • Nuveen reported no remaining Alto Neuroscience position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 139,953 Alto Neuroscience shares in Q2 2025, an estimated $302K.
  • Nuveen first reported a position in Alto Neuroscience in Q2 2024 and held it in 4 quarters.
  • Nuveen's Alto Neuroscience position peaked at $2.3M in Q3 2024.
  • 80 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.